Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» CAR-T
CAR-T
A late Christmas present for Allogene
EP Vantage
Mon, 01/10/22 - 11:27 am
Allogene
JPMHC 2022
FDA
CAR-T
Gilead’s Yescarta in line for $1.5B sales in earlier lymphoma thanks to game-changing data, fast production: analyst
Fierce Pharma
Thu, 12/16/21 - 11:57 pm
Gilead Sciences
Yescarta
CAR-T
Why Legend Biotech Shares Plummeted 17.6% Wednesday
Motley Fool
Wed, 12/15/21 - 11:47 pm
Legend Biotech
CAR-T
cancer
Genentech's tocilizumab shortage due to Covid-19 now hits CAR-T recipients, with FDA offering alternatives to help
Endpoints
Mon, 12/13/21 - 11:01 am
Genentech
tocilizumab
COVID-19
CAR-T
drug shortages
ASH: Another 'off-the-shelf' cell therapy leader shows durability issues, raising renewed concerns about emerging field
Endpoints
Sun, 12/12/21 - 11:26 pm
ASH2021
Precision Biosciences
CAR-T
relapsed or refractory non-Hodgkins lymphoma
ASH: Bristol Myers' Breyanzi, Gilead's Yescarta lock horns in race to move CAR-T therapy to earlier lymphoma
Fierce Pharma
Sat, 12/11/21 - 09:22 pm
Gilead Sciences
Yescarta
Bristol Myers Squibb
Breyanzi
CAR-T
lymphoma
Adicet soars on early responses to gamma delta CAR-T therapy
Fierce Biotech
Mon, 12/6/21 - 10:49 am
Adicet Bio
CAR-T
cell therapy
ADI-001
clinical trials
B-cell non-Hodgkin lymphoma
What to Expect at ASH: CAR T Results in Lymphoma, Data on IDH1+ AML, and More
OBR Oncology
Wed, 11/24/21 - 10:23 am
ASH2021
CAR-T
lymphoma
Yescarta
Tibsovo
blood cancers
COVID-19
AML
SITC: Cellectis' off-the-shelf CAR-T for pancreatic cancer and mesothelioma shows activity in mice
Fierce Biotech
Fri, 11/12/21 - 11:41 am
Cellectis
CAR-T
cancer
pancreatic cancer
mesothelioma
SITC
Takeda-backed Poseida puts off-the-shelf CAR-T in its basket, places autologous therapy back on the shelf
Fierce Biotech
Wed, 11/10/21 - 10:22 am
Poseida Therapeutics
CAR-T
BCMA
Takeda
FDA pushes back decision on J&J, Legend's BCMA CAR-T
Endpoints
Tue, 11/2/21 - 10:42 am
JNJ
Legend Biotech
FDA
CAR-T
cilta-cel
VCs back Leucid to trial CAR-T twist in ovarian cancer patients
Fierce Biotech
Thu, 10/21/21 - 10:40 am
Leucid Bio
CAR-T
ovarian cancer
clinical trials
venture capital
Triumvira is Creating a Different Picture for Cancer Patients
BioSpace
Wed, 09/22/21 - 11:36 pm
Triumvira
CAR-T
cancer
solid tumors
A year after a death and accompanying trial hold, Poseida hopes for reprieve with early solid tumor CAR-T data
Fierce Biotech
Tue, 08/31/21 - 11:05 am
Poseida Therapeutics
clinical trials
patient deaths
solid tumors
CAR-T
Gilead wins reversal of $1.2B fine in CAR-T patent fight with Bristol Myers
Fierce Pharma
Thu, 08/26/21 - 08:52 pm
Gilead Sciences
Kite Pharma
CAR-T
patents
Bristol Myers Squibb
New fault lines emerge in CAR-T therapy
EP Vantage
Tue, 08/24/21 - 10:43 am
CAR-T
Novartis
Kymriah
Bristol Myers Squibb
Beyanzi
Gilead Sciences
Yescarta
clinical trials
Novartis-backed Penn study proposes boosting CAR-T responses in CLL by waking up 'war weary' T cells
Fierce Biotech
Tue, 08/17/21 - 10:20 am
Novarts
CAR-T
CLL
Kymriah
Gilead's Kite earns second-line win for CAR-T Yescarta, setting up a battle over earlier blood cancer patients
Endpoints
Mon, 06/28/21 - 10:51 am
Gilead Sciences
Kite Pharma
Yescarta
relapsed or refractory diffuse large B-cell lymphoma
CAR-T
BMS will file for earlier-line use of Breyanzi in lymphoma after trial win
Pharmaforum
Fri, 06/11/21 - 10:49 am
Bristol Myers Squibb
CAR-T
Breyanzi
large B-cell lymphoma
Novartis
Gilead Sciences
FDA
Bristol Myers' CAR-T Breyanzi busts out a win in earlier-line lymphoma, potentially cracking open an expanded market
Endpoints
Thu, 06/10/21 - 10:50 am
Bristol-Myers Squibb
CAR-T
Breyanzi
B cell lymphoma
Pages
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »